First Page | Meta Content | |
---|---|---|
Document Date: 2015-04-22 23:39:46Open Document File Size: 595,13 KBShare Result on FacebookCityDocetaxel / /CompanyAEs / Differenc HR Ind. / RR Ind. / The New England Journal / ASTELLAS PHARMA AUSTRALIA PTY LTD / ITT / /CurrencyUSD / /EventFDA Phase / /FacilityConsumer Comments facility / /IndustryTermtreatment of patients with mCRPC whose disease / treatment of metastatic prostate cancer / treatment of metastatic castration-resistant prostate cancer / prescription processing / treatment algorithm / /MedicalConditioninsomnia / metastatic prostate cancer / earlier disease / hypertension / cancer / resistant metastatic carcinoma / disease / headache / castration-resistant prostate cancer / seizures / mCRPC whose disease / progressive disease / end-stage disease / mutated androgen-receptor causing disease / metastatic castration-resistant prostate cancer / pain / fatigue / skeletal metastases / earlier stage disease / prostate cancer / resistant prostate cancer / /MedicalTreatmentchemotherapy / oral therapy / /OrganizationWorld Health Organization / Data Monitoring Committee / FDA / AB PLA / /PositionGovernor / Minister / nurse / /Productprednisolone / flutamide / Enzalutamide Capsules / bicalutamide / prednisone / 202379Orig1s000StatR / enzalutamide / 202379Orig1s000PharmR / ABI-301 / /ProvinceOrStateIndiana / /PublishedMediumthe New England Journal of Medicine / Journal of Clinical Oncology / /RegionNew England / /Technologytreatment algorithm / submission Trial ID Protocol / chemotherapy / pdf / /URLwww.msac.gov.au / http /SocialTag |